Health
New STRENGTH Analysis Reignites Debate on Omega-3 CV Benefits – Medscape
The new analysis showing no benefits linked to higher achieved levels of EPA casts doubt over the use of high-dose omega-3 fatty acid products for preventing cardiovascular…
Questions over the cardiovascular benefits shown in the REDUCE-IT trial with icosapent ethyl, a high-dose eicosapentaenoic acid (EPA) product, have been reignited with a new analysis from the STRENGTH trial showing no benefit of a high-dose combined omega-3 fatty acid product in patients who achieved the highest EPA levels and no harm in those with the highest levels of docosahexaenoic acid (DHA).
STRENGTH investigator Steven Nissen, MD, said these new results add to concerns about the positive…
-
Noosa News13 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General11 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
General19 hours agoQueensland announced as 2027 Women’s Softball World Cup host in first Australian event since 1965
-
Noosa News21 hours agoInquest into Rosemarie Campbell’s death three days after gastric bypass surgery hears of ‘massive loss’ to family